|  | Galcanezumab | |
---|---|---|---|
Placebo N = 1451 n (%) | 120 mg N = 705 n (%) | 240 mg N = 730 n (%) | |
Hypersensitivity SMQ | 40 (2.8) | 36 (5.1)c | 33 (4.5) |
 Rash | 17 (1.2) | 8 (1.3) | 10 (1.4) |
 Injection site rash | 2 (0.1) | 6 (0.9)c | 4 (0.6) |
 Dermatitis contact | 4 (0.3) | 3 (0.4) | 4 (0.6) |
 Rhinitis allergic | 3 (0.2) | 3 (0.4) | 4 (0.6) |
 Hypersensitivity | 0 (0.0) | 3 (0.4)c | 2 (0.3)c |
 Injection site hypersensitivity | 0 (0.0) | 1 (0.1) | 3 (0.4)c |
 Dermatitis allergic | 0 (0.0) | 3 (0.4)c | 0 (0.0) |
 Eczema | 3 (0.2) | 1 (0.1) | 2 (0.3) |
 Rash pruritic | 0 (0.0) | 2 (0.3)c | 1 (0.1) |
 Urticaria | 5 (0.3) | 2 (0.3) | 1 (0.1) |
 Injection site urticaria | 1 (0.1) | 1 (0.1) | 1 (0.1) |
 Rash generalized | 1 (0.1) | 1 (0.1) | 1 (0.1) |
 Rash papulosquamous | 0 (0.0) | 1 (0.1) | 1(0.1) |
 Dermatitis atopic | 1 (0.1) | 0 (0.0) | 1(0.1) |
 Eye allergy | 0 (0.0) | 1 (0.1) | 0 (0.0) |
 Pruritus allergic | 0 (0.0) | 1 (0.1) | 0 (0.0) |
 Rash erythematous | 1 (0.1) | 0 (0.0) | 1 (0.1) |
 Rash maculo-papular | 1 (0.1) | 1 (0.1) | 0 (0.0) |
 Bronchospasm | 1 (0.1) | 0 (0.0) | 0 (0.0) |
 Conjunctivitis allergic | 1 (0.1) | 0 (0.0) | 0 (0.0) |
 Drug hypersensitivity | 1 (0.1) | 0 (0.0) | 0 (0.0) |